about
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the fiel...
Read More
22.91
-0.74
(-3.13%)
917.0K
XNAS Volume
XNAS 29 Jul, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Nektar Therapeutics is on 08 Aug 2025 for the purpose of Nektar Therapeutics Second Quarter Earnings Results for 2025
See details
Low Financial Strength
Expensive Valuation
Technically Moderately Bullish
Momentum Trap
These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked.
View Similar
Embed DVM
Nektar Therapeutics Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..